Cantor Fitzgerald: 18 Drug Companies With Catalysts Worth Watching

The biotech analysts at Cantor Fitzgerald have a packed calendar: here are some of the dates they’re tracking and why they’re important.

  • Mallinckrodt PLC MNK is expected to release Phase 4 interim Acthar data for multiple sclerosis at the end of May, rheumatoid arthritis in June and systemic lupus erythematosus at some point in the second quarter.
  • Mylan NV MYL’s Neulasta and Advair biosimilars have June 4 and June 27 Target Action Dates, respectively. Cantor forecast June oral arguments for challenged Restasis patents and a second-quarter launch of Cimduo.
  • Teva Pharmaceutical Industries Ltd (ADR) ADR TEVA’s injectable CGRP fremanezumab has a June 16 PDUFA date, and Cantor anticipates approval and launch before the end of the year.
  • Valeant Pharmaceuticals Intl Inc VRX is expected to secure approval for Duobrii June 18 and release Phase 3 data for IPD-123 in the second quarter.
  • Arsanis Inc ASNS will report Phase 2 interim results for ASN100 in late June.
  • Dermira Inc DERM’s DRM04 has a June 30 PDUFA date, and management will host an investor day May 24.
  • Nabriva Therapeutics PLC - ADR NBRV is expected to report Phase 3 Lefamulin data in late spring.
  • Amneal Pharmaceuticals Inc AMRX plans to launch generic Welchol and begin its Rytary trial with Teva sometime in the second quarter.
  • Aclaris Therapeutics Inc ACRS is expected to release Phase 2 data for ATI-502 in the second quarter.
  • Shire PLC (ADR) SHPG anticipates approval for its Covington manufacturing facility in June or July.
  • Heron Therapeutics Inc HRTX expects top-line results for its HTX-011 studies toward the end of the second quarter.
  • Cidara Therapeutics Inc CDTX plans to announce a development candidate midyear.
  • Spero Therapeutics Inc SPRO will report Phase 1 data for SPR994 by mid-2018 with the second quarter bringing results for a Phase 1b study of SPR741 and preclinical study of SPR206. SPR994 will begin a Phase 3 trial at the end of the year.
  • Theravance Biopharma Inc TBPH will report Phase 2a data for TD-9855 by the end of July, has a Nov. 13 PDUFA date for TD-4208 and will begin reporting Phase 1b data for its JAK inhibitor in the back half of 2018.
  • Allergan plc AGN has a PDUFA date for Esmya in August; anticipates Sarecycline approval and the release of Abicipar Phase 3 data in the second half of 2018; and will report Rapastinel Phase 3 data in 2019. Cantor Fitzgerald expects Phase 2b data for oral CGRP atogepant and Phase 2 data for pilocarpine/oxymetazoline in the second half of 2018.
  • Endo International PLC ENDP will report Phase 3 data for Xiaflex by the first quarter of 2019.
  • Paratek Pharmaceuticals Inc PRTK will report Phase 2 data for Omadacycline cUTI in the second half of 2019.
  • Opko Health Inc. OPK is expected to release interim Phase 2b data for OPK88004.

Related Links:

Benzinga's Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More

The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorBiotechNewsFDATop StoriesAnalyst RatingsGeneralCantor Fitzgerald
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!